home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

75 76 Next >

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

November 08, 2023

From AstraZeneca

Via Business Wire

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Price Over Earnings Overview: AstraZeneca ↗

November 06, 2023

Via Benzinga

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs

November 03, 2023

Via Investor Brand Network

Topics Intellectual Property

Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry ↗

October 30, 2023

Via Benzinga

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

November 03, 2023

From AstraZeneca

Via Business Wire

7 Evergreen Stocks for Long-term Wealth Generation ↗

November 03, 2023

These are the stocks to buy for long-term wealth as they represent companies that will continue to grow and boost shareholder returns.

Via InvestorPlace

Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today? ↗

November 01, 2023

Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company

Via Benzinga

Why Is Cellectis (CLLS) Stock Up 175% Today? ↗

November 01, 2023

Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 01, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!

Via InvestorPlace

Can Diabetes, Weight-Loss Drugs Get Even Better?

October 30, 2023

Via Investor Brand Network

Can Diabetes, Weight-Loss Drugs Get Even Better?

October 30, 2023

EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

October 28, 2023

A couple of these stocks might not be available for under $100 for too much longer.

Via The Motley Fool

Why Is LumiraDx (LMDX) Stock Down 35% Today? ↗

October 24, 2023

LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership.

Via InvestorPlace

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

October 24, 2023

From AstraZeneca

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 23, 2023

Via Benzinga

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

October 23, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

Why Is LumiraDx (LMDX) Stock Up 323% Today? ↗

October 23, 2023

LumiraDx stock is rising higher on Monday with heavy trading of LMDX shares after announcing a partnership with AstraZeneca.

Via InvestorPlace

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

October 22, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

October 21, 2023

From AstraZeneca

Via Business Wire

Stock Market Struggles As Treasury Yields Soar; Tesla, Nvidia Among Notable Losers: Weekly Review ↗

October 20, 2023

The major indexes saw significant loses as Treasury yields soared.

Via Investor's Business Daily

Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development ↗

October 20, 2023

Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.

Via Benzinga

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

October 20, 2023

From AstraZeneca

Via Business Wire

Why Is AstraZeneca Stock Trading Lower Today? ↗

October 18, 2023

AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some...

Via Benzinga

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock ↗

October 18, 2023

The companies are hoping to use antibody drug conjugates in lung cancer patients.

Via Investor's Business Daily

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com